Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEDILANID-D vs LANOXIN PEDIATRIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
Heart failure,Atrial fibrillation,Atrial flutter
Heart failure,Atrial fibrillation,Atrial flutter
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Hepatic (minor); primarily renally excreted unchanged.
Hepatic via glucuronidation; substrate of P-glycoprotein; renal excretion of unchanged drug.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
25-30% bound to plasma albumin.
20-30% bound to plasma proteins, primarily albumin.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
Vd is 5-10 L/kg in adults, indicating extensive tissue binding; higher in infants (up to 16 L/kg) with reduced protein binding.
Oral: 70-80%; IV: 100%.
Oral: 60-80% (Lanoxin Pediatric elixir 70-85%); variable due to first-pass metabolism and P-glycoprotein effects.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50%; GFR <10 m L/min: reduce dose by 50-75% or consider alternative.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50-75% with monitoring.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Oral loading: 10-20 mcg/kg in divided doses over 24 hours; maintenance: 5-10 mcg/kg once daily. IV loading: 10-15 mcg/kg; maintenance: 4-8 mcg/kg once daily. Monitor levels.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
Reduced dose: initial maintenance 0.0625-0.125 mg once daily due to age-related renal impairment and increased sensitivity. Monitor renal function and serum digoxin levels.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
Digitalis toxicity can cause severe arrhythmias; monitoring of serum digoxin levels required.
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Risk of toxicity in renal impairment, electrolyte disturbances, and drug interactions; monitor digoxin levels and ECG.
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
Hypersensitivity to digoxin, ventricular fibrillation, digitalis toxicity.
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
Avoid concurrent ingestion of high-fiber foods, as they may reduce absorption. Separate dosing by at least 2 hours from meals rich in bran, oats, or other fiber. Maintain consistent dietary potassium intake; both low and high potassium can affect digoxin toxicity. Grapefruit juice may increase absorption; avoid excessive consumption.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restriction due to transplacental transfer and maternal hemodynamic changes.
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
Digoxin is excreted into breast milk with an M/P ratio of approximately 0.6–0.9. Levels are low (typically <1 ng/m L) and considered compatible with breastfeeding; however, monitor infant for signs of toxicity including bradycardia and feeding difficulties.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
Due to increased volume of distribution and renal clearance in pregnancy, higher doses (up to 30–50% increase) may be required to maintain therapeutic serum levels. Monitor serum digoxin concentrations and titrate to therapeutic range (0.5–0.9 ng/m L in heart failure; 0.8–2.0 ng/m L for arrhythmias).
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Lanoxin Pediatric (digoxin) requires monitoring of renal function and serum electrolytes (especially potassium and magnesium) due to narrow therapeutic index. Check digoxin levels 6-8 hours after dose; therapeutic range 0.8-2.0 ng/m L. Avoid concurrent use with drugs that affect renal function or electrolyte balance.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
Take exactly as prescribed at the same time each day. Do not double the dose if you miss one.,Do not stop taking without consulting your doctor. Sudden withdrawal may worsen heart condition.,Watch for signs of toxicity: nausea, vomiting, diarrhea, vision changes (blurring, yellow-green halos), confusion, irregular heartbeat.,Keep all appointments for blood tests to monitor levels and kidney function.,Contact your doctor before taking any new medications, including over-the-counter drugs and supplements.,Limit alcohol and avoid potassium-sparing diuretics unless prescribed. Maintain consistent dietary intake of potassium-rich foods.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEDILANID-D vs LANOXIN PEDIATRIC, answered by our medical review team.
CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. LANOXIN PEDIATRIC is a Cardiac Glycoside that works by Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEDILANID-D and LANOXIN PEDIATRIC depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. The standard adult dose of LANOXIN PEDIATRIC is: Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEDILANID-D and LANOXIN PEDIATRIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. LANOXIN PEDIATRIC is classified as Category C. First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restric. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.